Status:
TERMINATED
Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
Lead Sponsor:
Revance Therapeutics, Inc.
Conditions:
Skin Aging
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the long-term safety of botulinum toxin type A for the treatment of moderate to severe crow's feet lines after repeat application.
Eligibility Criteria
Inclusion
- Moderate to severe crow's feet lines
- Female or male, 18 years of age and above and in good general health
- Women of childbearing potential must agree to use an effective method of birth control during the course of the study
Exclusion
- Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A
- Muscle weakness or paralysis, particularly in the area receiving study treatment
- Active skin disease or irritation at the treatment area
- Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart
- Treatment with botulinum toxin type A for crow's feet lines in the last 3 months
- Chemical peel during the 9 months prior to treatment
- Use of prescription retinoid products during the 3 months prior to treatment
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
311 Patients enrolled
Trial Details
Trial ID
NCT01818076
Start Date
February 1 2013
End Date
December 1 2013
Last Update
May 7 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nashville Centre for Laser and Facial Surgery
Nashville, Tennessee, United States, 37203